Enoblituzumab, previously known as TJ-271 or MGA271, represents a novel antibody specific to CD33, a marker found predominantly on blood cells. This antibody works as an bispecific therapy, simultaneously attaching to https://rebeccagmbg819612.mpeblog.com/74719090/enoblituzumab-a-deep-dive-into-tj-271-and-mga271